Sign in Subscribe
Pharmaceutical industry

Generex Biotechnology Corporation Exhibits at American Association of Diabetes Educators Conference

Strategic Insights

— 1 min read

Generex Biotechnology Corporation, the leader in metabolic diseases drug delivery through the inner lining of the mouth, announced its presence at the American Association of Diabetes Educators (AADE) 33rd Annual Meeting & Exhibition. The conference, held August 10-12, 2006, at the Los Angeles Convention Center, aimed to provide the latest information on diabetes self-management training and care. Generex exhibited its proprietary technologies for developing products that help patients with diabetes control and manage the disease.

Key Takeaways:

  • Generex Biotechnology Corporation, a leader in metabolic diseases drug delivery, exhibited at the American Association of Diabetes Educators 33rd Annual Meeting & Exhibition.
  • The conference featured 100+ educational sessions on diabetes self-management training and care, with an exhibit hall showcasing hands-on product introductions and information.
  • Generex showcased its proprietary technologies for developing products that help patients with diabetes control and manage the disease, including its flagship product, Generex Oral-lyn(TM).
  • Dr. Gerald Bernstein, Generex's Vice-President for Medical Affairs and a former President of the American Diabetes Association, was present at the Generex booth to discuss the Company's products.
  • The American Association of Diabetes Educators is a multidisciplinary professional membership organization of healthcare professionals dedicated to integrating successful self-management as a key outcome in the care of people with diabetes and related conditions.

Statistics:

  • Generex Biotechnology Corporation is engaged in the research and development of drug delivery systems and technologies.
  • The Company's proprietary platform technology delivers drugs into the human body through the oral cavity (with no deposit in the lungs).
  • Generex has developed a proprietary liquid formulations that allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device.
  • The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes.

Sources:

  • Generex Biotechnology Corp.
  • American Association of Diabetes Educators (www.aadenet.org)

Read more